Xeljanz Oral Solution Alternatives Compared
| Xeljanz Oral Solution (tofacitinib) | Humira (adalimumab) | Xeljanz (tofacitinib) |
|
|---|
| Xeljanz Oral Solution (tofacitinib) | Humira (adalimumab) | Xeljanz (tofacitinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Polyarticular Juvenile Idiopathic Arthritis. Xeljanz Oral Solution may also be used for purposes not listed in this medication guide. |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Xeljanz is a Janus kinase (JAK) inhibitor that may be used to reduce inflammation associated with several conditions such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, or... View more |
Related suggestions Polyarticular Juvenile Idiopathic Arthritis
|
|||||||||||||||
| More about (tofacitinib) | More about Humira (adalimumab) | More about Xeljanz (tofacitinib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Humira has an average rating of 6.4 out of 10 from a total of 699 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 31% reported a negative effect. |
Xeljanz has an average rating of 5.7 out of 10 from a total of 145 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 40% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Xeljanz Oral Solution side effects |
View all Humira side effects |
View all Xeljanz side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
| Lower cost generic approved |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Humira prices |
View all Xeljanz prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other tofacitinib brands include: Xeljanz, Xeljanz XR | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other tofacitinib brands include: Xeljanz Oral Solution, Xeljanz XR | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
3 hours |
480 hours |
3 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 659 drugs are known to interact with Xeljanz Oral Solution:
|
A total of 552 drugs are known to interact with Humira:
|
A total of 659 drugs are known to interact with Xeljanz:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
December 31, 2002 |
November 06, 2012 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.